50/FIFTY

Today's stories, rewritten neutrally

Finance1d ago

Multiple Companies Report Q2 and Long-Term Revenue Guidance Updates

Several publicly traded companies provided updated revenue forecasts and business outlooks during recent earnings communications.

Synthesized from 7 sources

Seven companies across various industries provided updated revenue guidance and business outlook information to investors this week.

Andersen Corporation projected revenue of $980 million to $1 billion for 2026 while raising its inorganic revenue outlook to $55 million. The window and door manufacturer's updated forecasts reflect expectations for continued growth in the construction materials sector.

In the medical device space, Neuropace announced a 2026 revenue outlook of $99 million to $101 million while targeting underlying RNS growth of 21% to 23%. The neurostimulation device company's projections indicate continued expansion in the neurological treatment market.

Fitness company Beachbody expects second-quarter revenue between $46 million and $51 million as its Shakeology nutrition product line expands distribution to Sprouts Farmers Market and Vitamin Shoppe retail locations. The expanded retail presence represents a significant distribution milestone for the direct-to-consumer fitness brand.

National CineMedia, which operates advertising networks in movie theaters, forecasted second-quarter revenue of $57 million to $63 million with adjusted OIBDA of $1 million to $5 million. The cinema advertising company cited ongoing cost-savings initiatives as part of its operational strategy.

Black Rock Coffee reaffirmed its 2026 outlook of $255 million to $257 million in revenue alongside plans for 36 new store locations. The coffee chain indicated it is monitoring market densification opportunities in the Phoenix metropolitan area.

Biotechnology companies Lineage and Fractyl also provided operational timeline updates, with Lineage targeting operations extending into the second quarter of 2028 as it launches COR1 and scales ILT1 manufacturing, while Fractyl targets early fourth-quarter 2026 for REMAIN-1 pivotal study results.

Sources (7)

Bias Scale:
LeftCenterRight

Comments

No comments yet. Be the first!